Clinical Trials Browser

Phase 2 × Breast Neoplasms × Afatinib × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02115048 2019-12-26

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Phase 2 Terminated

44 enrolled 15 charts

Breast Neoplasms

NCT01271725 2019-06-17

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Phase 2 Completed

74 enrolled 16 charts

Breast Neoplasms

NCT02511847 2016-04-15

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01441596 2015-09-07

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Phase 2 Completed

121 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00431067 2014-06-09

Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

Phase 2 Completed

41 enrolled 9 charts

Breast Neoplasms

NCT00425854 2013-12-31

An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer

Phase 2 Completed

50 enrolled 13 charts

Breast Neoplasms

NCT00826267 2013-12-31

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Phase 2 Completed

29 enrolled 9 charts

Breast Neoplasms

NCT00708214 2013-12-30

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

Phase 2 Completed

28 enrolled 20 charts

Breast Neoplasms

NCT01531764 2013-10-18

BIBW 2992 (Afatinib) and Vinorelbine

Phase 2 Terminated

Breast Neoplasms